Note 2   Business Combination The acquisition below was accounted for as a business combination and, accordingly, the Company has included the results of operations of the acquired entity in its consolidated statements of income from the date of acquisition. Neither separate financial statements nor pro forma results of operations have been presented because the acquisition does not meet the quantitative materiality tests under Regulation S-X. Acquisition of GTI Diagnostics In December 2010, the Company acquired GTI Diagnostics, a privately held specialty diagnostics company focused on the transplantation, specialty coagulation and transfusion-related blood bank markets, for $53.0 million on a net-cash basis. As a result of the acquisition, GTI Diagnostics became a wholly owned subsidiary of the Company. The Company financed the acquisition with cash on hand. The purchase price allocation for the acquisition of GTI Diagnostics set forth below is preliminary and subject to change as more detailed analysis is completed and additional information with respect to the fair value of the assets and liabilities acquired becomes available. The Company expects to finalize the purchase price allocation during the remainder of 2011. The preliminary allocation of the purchase price for the Company s acquisition of GTI Diagnostics is as follows (in thousands): Total purchase price $ 53,000 Net working capital $ 7,881 Fixed assets 1,001 Goodwill 28,005 Deferred tax liabilities (11,137 ) Other intangible assets 32,100 Liabilities assumed (4,850 ) Allocated purchase price $ 53,000 The fair values of the acquired identifiable intangible assets with definite lives are as follows (in thousands): Patents $ 10,600 In-process research and development 11,900 Customer relationships 3,500 Trade secrets 6,100 Total $ 32,100 The amortization periods for the acquired identifiable intangible assets with definite lives are as follows: six to nine years for patents, ten years for customer relationships, 20 years for trade secrets, and an estima